Dec. 15 Quick Takes: Singlera raises $150M for cancer dx; plus AnGes-Emendo, Entresto, vTv and Unity
Cancer screening play Singlera raises megaround
Singlera Genomics Inc. raised $150 million in a series B round led by the CICC Kai Tak Innovative Biomedicine Fund, and co-led by Detong Capital and Furong Investment. Fellow new investors include Huamei International, Linden Asset Group, WuXi Capital, FutureX Skyline Capital, Shanghai Free Trade Zone Fund, and series A investors Greenpine Capital, Prosperico Ventures and Proxima Ventures. Singlera plans to use the funds in part to expand its early cancer screening product R&D and prospective studies into pan-cancer early screening. Founded in 2014, the non-invasive genetic diagnosis company has R&D and business operations outposts in La Jolla, Calif., and Shanghai.
AnGes takes out CRISPR play Emendo
AnGes Inc. (Tokyo:4563) has acquired CRISPR gene editing company Emendo Biotherapeutics Inc. at a valuation of $250 million. The Japanese biopharma had invested in Emendo’s series B round in January; the Israeli company, which has operations in New York City and Tel Aviv, was founded in 2015 by OrbiMed and Takeda Ventures...